Cancer is becoming a chronic condition requiring continuous patient follow-up. Current tests lead to delayed clinical visibility and suboptimal guidance for managing advanced disease. METHYS Dx delivers the necessary paradigm shift. Our blood-based assays detect tumor DNA with high sensitivity 10 times faster and at 20 times lower cost than existing liquid biopsy solutions. Backed by robust IP, already launched RUO products, and a team with previous successful exits, we are actively capturing the $1B advanced cancer follow-up market.

Completed 30 a day ago
176 investors
Investment achieved
890.038€
Target
800.000€
Invested
111.3%
111.3% INVESTED
This campaign was live:
From: 12 March 2026
Until: 13 May 2026
Maturity

In the market

Premoney valuation

5.882.353€

Estimated exit

2028-2031

Sector

Diagnostics

Equity offered

12%

Minimum investment

1.000€

Paris flag
Equity L
Tax deduction L
close modal
Share this opportunity

Share on your social channels

Select the social platform

Share this project on your website.

Copy and paste the following code into your content.

Overview: METHYS Dx

Valuation 5.882.353€
Estimated return x28
% Offered 12%
Estimated exit 2028-2031

M*Detect is our product line for the follow-up of advanced cancer in real-time offering highly sensitive detection of cancer biomarkers from blood in one day for less than 50€

We have launched five ready-to-use M*Detect kits for colorectal, pancreatic, gastric, lung, and endometrial cancers for which we have already acquired more than 14 customers with 60% reorder rate

Our proprietary biomarkers have been validated with more than 20 peer-reviewed clinical studies including thousands of cancer patient samples  

METHYS Dx biomarkers are prognostic of cancer evolution and patient‚ survival‚ and predictive of therapy response

M*Detect kits enable personalized cancer care with real-time monitoring of advanced disease, a $1B market with no pertinent solutions

METHYS Dx products build on a strong portfolio of biomarker and technology patents and more than 10 years of collaborative academic and clinical research

Our Mission: Enable real-time cancer patient follow-up to personalize care, improve quality of life, and extend survival.

Cancer care is evolving and treatment options expanding, but tools for real-time follow-up are not keeping pace. Over 50 million people have been diagnosed with cancer in the last 5 years and are still living with the disease: oncologists require tools for patient follow-up. Current standard of care relies on imaging (leading to delay in detecting progression) and analysis of protein markers (limited by low sensitivity and specificity). There is a need for a universal, rapid, minimally-invasive, cost-effective tool to predict outcomes, guide decisions, and monitor treatment effectiveness. METHYS Dx delivers exactly that. From a simple blood draw, our technology enables sensitive, fast, and affordable follow-up of cancer evolution. It is based on the detection of proprietary methylation signatures measuring circulating tumor DNA (ctDNA) – a dynamic biomarker of cancer progression – without requiring tumor tissue biopsy or complex platforms. Intended for broad accessibility, our solutions fit any standard clinical or research lab.

Patient journey

METHYS Dx products grounded in strong academic research and clinically validated

Built on more than a decade of cutting-edge translational research at leading institutions including Cordeliers Research Center and ESPCI, METHYS Dx developed products for cancers of the colon, pancreas, stomach, lung and endometrium (and more pending). The science and real-world diagnostic potential are backed by 20+ high-impact publications and >75 presentations in international conferences & workshops.

METHYS Dx has secured broad intellectual property protection for its biomarkers, molecular signatures, and detection technologies. The company holds an exclusive license and/or assignment for patents covering differentiated biomarkers and cancer-specific methylation signatures.

A committed team with a shared vision

METHYS Dx unites multidisciplinary experts with a bold vision: transforming liquid biopsy into actionable diagnostics. Our team combines world-class expertise in translational research, biomarker discovery, technology innovation, product development, business strategy, and commercial execution. The company was founded in 2021 by leading scientists, including Drs. Valérie Taly, Pierre Laurent-Puig, Yannick Rondelez, and Guillaume Gines. Our foundation was strengthened by industry leaders like Dr. Magali Droniou, co-founder of Stilla Technologies (a digital PCR pioneer acquired by Bio-Rad for $275M); Dr. Brian Hutchison, bringing deep experience in leadership, product development, and business operations; and Emmanuel Martin, with 25 years of experience in commercializing oncology products.

With guidance from renowned advisors in liquid biopsy, regulatory strategy, technology development, and clinical practice, METHYS Dx is poised for rapid growth. Our unique mix of scientific excellence, clinical experience, and entrepreneurial drive positions us to deliver on the commercialization strategy and product roadmap to capture a large market opportunity arising from an urgent medical need.

M*Detect™: our first product line for advanced cancer follow-up

M*Detect™ uses proprietary biomarkers and commercially available digital PCR, a technology for which the team has extensive experience, to deliver highly sensitive ctDNA detection with rapid turnaround and affordability. Five ready-to-use kits cover colorectal, pancreatic, gastric, lung, and endometrial cancers. Starting from <1 ml of plasma, M*Detect delivers clinically relevant results in a day for ~50€, compared with 1-2 weeks and >1,000€ for competitor tests.

METHYS Dx acquired 14 customers and generated 300k€ to date from prototype kit sales and services. 60% of our customers have already re-ordered. Current kits are Research Use Only (RUO), and IVD-marked kits are planned for 2027. 

workflow

Why Invest in METHYS Dx now?

The company has minimized fundamental risks and is uniquely positioned to become a major player in oncology diagnostics.

  • Large market opportunity: Real-time follow-up of advanced cancers, a $1B market, remains unsolved.
  • Low technical risk: Proprietary ctDNA biomarkers and rapid, inexpensive dPCR tests are highly differentiated and validated through academic research, clinical partners and early adopters.
  • Mitigated competitive risk: Robust IP, strong biomarker expertise, extensive product portfolio clinical validation and an innovation roadmap represent a formidable moat to competition.
  • Low execution risk: Experienced and expert team; strong relationships with founders, advisors, and collaborators; pathways to joint commercialization (e.g., with digital PCR manufacturers) establish a firm foundation for efficient execution of the business plan.
  • Outstanding ROI potential: Attractive valuation with huge market potential, evidenced by recent deals valued at >$200M, makes it a compelling opportunity with a potential ROI >28x.
In Capital Cell's own words

Accessibility remains one of the main problems to monitor cancer accurately. Today, patients need frequent and sensitive checks over time, but standard techniques remain slow, expensive, and difficult to implement routinely in many hospitals. METHYS Dx’s proposal is to solve this problem with proprietary technology that integrates with currently available equipment, a clear market, and a team with both scientific and business experience.

The company focuses on very frequent cancers—lung, colorectal, gastric, pancreatic, and endometrial—which together represent about 30% of cancer cases in the world (some 6.5 million a year). In addition, it operates in the molecular diagnostics market, which is growing around 15% annually. Its key innovation is patented methylation signatures that allow standard digital PCR equipment to achieve a sensitivity in diagnosing cancer recurrence similar to much more complex and expensive technologies such as NGS sequencing. This is important because almost all clinical laboratories have PCR, while only about 20% of European hospitals have their own NGS equipment, with numbers much lower in regions like Latin America, Asia, or Africa. Many centers outsource these tests, which implies delays and higher costs.

The technology has already begun to show market interest. In its initial phase, with research-use-only (RUO) products, METHYS Dx has gained 14 corporate and institutional clients and has generated €160,000 in kit and service sales in 12 months. Furthermore, 60% of those clients have repeated orders, indicating that the product solves a real need.

To the scientific team, which has led METHYS Dx to obtain 7 patents and 20 publications, is added a management team with real experience in creating and scaling diagnostic companies, including a co-founder of Stilla Technologies, which was acquired for 275 million dollars. METHYS Dx presents a highly strategic exit profile, with exit potential based both on acquisition by diagnostic sector leaders—such as Qiagen or Bio-Rad—and on integration by key competitors looking to expand their technological capabilities.

Minimum investment: 1.000€
Type of exit expected: Sale of the company or IPO
Drag-along rights
The transaction will require the approval of investors representing at least 85% of shares in a General Assembly , including 100% of the founders.
Tag-along rights
The founders may transfer up to 20% of their shares without triggering the tag-along rights of minority investors.
Preferential liquidation rights
1X Preferential liquidation right for investors of this round
Anti-dilution rights
Tax deductions
Subscribing to the capital of a company, such as a JEU, allows you to benefit from an income tax reduction subject to meeting certain conditions. The subscriber must be a natural person, i.e., an individual or sole trader, domiciled for tax purposes in France, and undertake to hold the securities received in exchange for the subscription (shares or stocks) for a minimum period of five years. The amount of payments taken into account for the calculation of this tax reduction is limited to €50,000 for a single, widowed, or divorced person, and to €100,000 for a married or civil partnership couple subject to joint taxation. For more information, you can visit the website: entreprendre.service-public.fr.
Main risks

METHYS Dx operates in a highly competitive and litigious market dominated by large players like Natera and Guardant Health. This high-stakes environment presents a continuous Intellectual Property (IP) risk, potentially leading to patent confrontation or significant commercialization delays.

Currently, sales are limited to the Research Use Only (RUO) sector. The major turning point for investors lies in obtaining CE-IVDR and FDA certifications, which are essential for routine clinical use. Overcoming this regulatory milestone is the key to scaling revenue and opening the door to an exit at a significantly higher valuation.

Register now to see the full pitch of METHYS Dx.

Transforming a simple blood draw into real-time intelligence to guide personalized cancer care.
Register with your email

Already have an account? Please login here .